Spinocerebellar Ataxia 27B (SCA27B)

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Spinocerebellar Ataxia 27B (SCA27B) trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingNot Applicable

NCT06472557

Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)

This international, multi-center, multi-modal, and prospective observational cohort study aims to validate trial outcomes for capturing disease progression in S…

Czechia, Germany +2 more300 participantsStarted 2024-06-04

RecruitingPhase 3

NCT07185347

A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients Wit…

Spinocerebellar ataxias 27B (SCA27B) is caused by an expansion of ≥ 250 GAA triplets in the FGF14 gene and accounts for 15% of cerebellar ataxias (around 500 pa…

France70 participantsStarted 2025-10-21

Treatment: Fampridine 10 mg prolonged-release tablet (per os), Placebo (tablets per os)

Spinocerebellar Ataxia 27B (SCA27B)

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)

A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients Wit…

All recent trials (2 shown)

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

Spinocerebellar Ataxia Type 27B Natural History Study (SCA27B-NHS)

A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients Wit…

All recent trials (2 shown)